Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection

Bookmark and Share
Published: 24 Dec 2019
Views: 357
Rating:
Save
Prof Daniel Ryan - University of Rochester, Rochester, USA

Prof Daniel Ryan speaks to ecancer at the ASH 2019 meeting in Orlando about the quality of remission after daunorubicin and cytarabine liposome injection.

He outlines the parent study and results, before explaining this subgroup analysis and results.